Meat and meat products are one of the largest contributors to vitamin D dietary intakes. Little is known, however, about how different animal husbandry practices and/or finishing diets might affect the vitamin D content of the animal. Therefore, this study aimed to investigate the effect of bovine finishing diet (grass vs. concentrate) on the 25(OH)D plasma concentrations of cattle and subsequent vitamin D content in beef. Cattle were fed grass (n = 7) or concentrate (n = 9) finishing diets for 15 weeks prior to slaughter. Bovine blood samples were collected at slaughter and plasma aliquots were stored (−80 °C) until analysis. Beef top rump from each animal was chilled for an ageing period of 21 days, then homogenised and frozen (−80 °C) until analysis. Bovine plasma samples were analysed for circulating 25(OH)D3, and 25(OH)D2 (nmol/L), and raw beef muscle (top rump) samples were analysed for vitamin D metabolites; vitamin D3, vitamin D2, 25(OH)D3 and 25(OH)D2 (µg/kg), all by LC-MS/MS. Total vitamin D activity was defined: [vitamin D3 + (25(OH)D3 × 5) + vitamin D2 + (25(OH)D2 × 5)]. Statistical analysis was conducted by SPSS with independent t tests used to compare groups; significance level p < 0.05. Data were presented as mean ± SD. A significantly higher plasma 25(OH)D2 concentration was observed in the grass finished cattle compared to the concentrate group (43.18 ± 11.75 vs. 16.56 ± 1.58 nmol/L, p < 0.002). No difference in plasma 25(OH)D3 concentrations was observed between groups. In beef top rump, the grass finishing diet resulted in a significantly higher mean ± SD vitamin D2 [0.07 ± 0.05 vs. 0.01 ± 0.01 µg/kg] and 25(OH)D2 [0.70 ± 0.16 vs. 0.25 ± 0.07 µg/kg] compared to concentrate finishing diet (both p < 0.001). Moreover, beef from grass finished cattle demonstrated a significantly higher total vitamin D activity compared to those in the concentrate group [9.52 ± 2.43 vs. 6.78 ± 2.00 µg/kg, p < 0.05]. No difference was observed for muscle vitamin D3 or 25(OH)D3 between groups. In conclusion, a more favourable bovine vitamin D profile, driven by vitamin D2 metabolites specifically (not vitamin D3), is reported from a grass-based finished system, compared to concentrate finishing. Further research is required to understand the impact of these findings for both agriculture practices and human nutrition.

Background Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by dysfunction in social interactions, communications, and/or behaviour. Whilst the aetiology of ASD is poorly understood, a combination of genetic and environmental factors has been suggested to contribute to ASD pathophysiology. Vitamin D deficiency during pregnancy has shown to play a role in the development of maternal complications including preeclampsia, gestational diabetes, and infant conditions including bone and autoimmune diseases, respiratory illness and neurodevelopmental disorders. Recently studies have investigated the role of prenatal vitamin D status (25-hydroxyvitamin D [25(OH)D] concentrations) in the development of ASD in children. Objectives The aim of this review is to systematically search literature investigating the associations between maternal, cord or neonatal vitamin D status and the diagnosis of ASD in children. Methods A systematic search was conducted within Medline, EMBASE, PsycInfo and CINAHL databases using ‘pregnancy’, ‘vitamin D’ and ‘autism spectrum disorder’ as the main search concepts, to identify studies investigating the association between prenatal or neonatal vitamin D status and ASD diagnosis in children. The eligibility criteria were: (a) human based epidemiological studies; (b) available information on 25(OH)D concentrations during the prenatal period which included samples collected during pregnancy, from newborns at birth or cord blood samples; and (c) offspring that had a diagnosis of ASD. Results A total of 11 studies met the inclusion criteria, originating from four countries, and which were conducted between 2015 and 2020. Seven studies investigated associations between child ASD diagnosis and maternal vitamin D status, five investigated vitamin D status during the neonatal period and one investigated in associations with cord blood vitamin D status. Vitamin D status ranged from 8.4nmol/L (vitamin D deficiency) to 116nmol/L (vitamin D sufficiency). Six of the eight case-control studies reported a significantly lower vitamin D status in the ASD group compared to their controls. A majority of studies that had maternal insufficiency (25(OH)D <50nmol/L) observed associations with an increased risk of children developing ASD. Some studies investigating neonatal vitamin D status and child ASD diagnosis, have shown that a deficient status of ≤25nmol/L is associated with a higher risk of diagnosis compared to those with an insufficient status (≤50nmol/L) and above. There were no significant associations observed in the study investigating cord vitamin D status and child ASD diagnosis. Conclusions These results highlight that vitamin D insufficiency during pregnancy and the neonatal period may be a risk factor for ASD diagnosis in children. The findings of this systematic review suggest that vitamin D status should be optimised prior to and during pregnancy and early life to levels of >50 nmol/L to reduce the possible risk of development of ASD in children, albeit these findings are based on observational studies only. Further research is needed to investigate the effects on vitamin D supplementation to optimise vitamin D status and associations with child ASD diagnosis.

Background Maternal thyroid hormones facilitate optimal foetal neurodevelopment, however the exact role of the thyroid hormones on specific cognitive outcomes is unknown. Objectives This study aimed to investigate associations between maternal thyroid function and neurodevelopmental outcomes at 20 months in the Seychelles Child Development Study (SCDS, n=1535). Methods Maternal free thyroid hormones (fT3, fT4 and fTSH) were assessed at 28 weeks gestation with a range of child cognitive outcomes analysed at 20 months. Dietary iodine intake was analysed for a subset of women through a Food Frequency Questionnaire (FFQ) (n=422), with a median iodine intake of 233µg/d, slightly below the recommended iodine intake for pregnancy as advised by the WHO (>250µg/d). Linear regression analysis was used to test associations between serum concentrations of fT3, fT4 and fTSH and child cognitive outcomes. Thyroid hormones were analysed both as continuous data and also categorised as quintiles. 95% of mothers had optimal thyroid function based on their TSH concentrations. Results Results show that maternal fT3, fT4 and TSH were not significantly associated with any cognitive outcomes at 20 months in this high fish-eating population. However, a positive association, using quintiles for fT3, was reported for Motor Development Index (MDI; a subtest of the Bayley’s Scales of Infant Development), between Q3 vs Q4 (β 0.073; p 0.043) and for Q3 vs Q5 (β value 0.086; p 0.018). Conclusions Thus, it is possible mothers in our cohort, who largely have optimal thyroid function and iodine intakes, are able to regulate thyroid function throughout pregnancy to meet neurodevelopmental needs. However, it is likely that minor imbalances of fT3, as indicated from our quintile analysis, may impact offspring neurodevelopment. Thus, further investigation is warranted, particularly focusing on thyroid hormone fluctuation throughout pregnancy in relation to possible associations with infant neurodevelopment.

Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver a scientific opinion on Scientific and technical guidance for the preparation and presentation of applications for exemption from mandatory labelling of food allergens and/or products thereof. This guidance applies to food ingredients or substances with known allergenic potential listed in Annex II of Regulation (EU) No 1169/2011 or products thereof, and aims to assist applicants in the preparation and presentation of well-structured applications for exemption from labelling. It presents a common format for the organisation of the information to be provided and outlines the information and scientific data which must be included in the application, the hierarchy of different types of data and study designs, reflecting the relative strength of evidence which may be obtained from different study types, and the key issues which must be addressed in the application in order to assess the likelihood of a food allergen-derived preparation/foodstuff(s) triggering adverse reactions in sensitive individuals under the proposed conditions of use. This guidance document was adopted by the NDA Panel in 2013 and updated in 2017 to reflect the application of Regulation (EU) No 1169/2011. Upon request from the European Commission in 2020, it has been revised to inform applicants of new provisions in the pre-submission phase and submission application procedure set out in Regulation (EC) No 178/2002, as amended by Regulation (EU) 2019/1381 on the transparency and sustainability of the EU risk assessment in the food chain, that are applicable to all applications submitted as of 27 March 2021. (C) European Food Safety Authority, 2021

The health effects of vitamin D are well documented, with increasing evidence of its roles beyond bone. There is, however, little evidence of the effects of vitamin D on hospitalisation among older adults. This study aimed to prospectively determine the relationship of vitamin D status in older adults with hospital admission and emergency department (ED) attendance. Trinity University of Ulster Department of Agriculture (TUDA) is a large cross-sectional study of older adults with a community population from three disease-defined cohorts (cognitive dysfunction, hypertension, and osteoporosis). Participants included in this analysis were recruited between 2008 and 2012. ED and hospital admission data were gathered from the date of TUDA participation until June 2013, with a mean follow up of 3.6 years. Of the 3093 participants, 1577 (50.9%) attended the ED during the period of follow-up. Attendees had lower mean serum 25(OH)D concentrations than non-attendees (59.1 vs. 70.6 nmol/L). Fully adjusted models showed an inverse association between vitamin D and ED attendance (Hazard Ratio (HR) 0.996; 95% Confidence Interval (CI) 0.995–0.998; p < 0.001). A total of 1269 participants (41%) were admitted to hospital during the follow-up. Those admitted had lower mean vitamin D concentrations (58.4 vs. 69.3 nmol/L, p < 0.001). In fully adjusted models, higher vitamin D was inversely associated with hospital admission (HR 0.996; 95% CI 0.994–0.998; p < 0.001) and length of stay (LOS) (β = −0.95, p = 0.006). This study showed independent prospective associations between vitamin D deficiency and increased hospitalisation by older adults. The need for further evaluation of current recommendations in relation to vitamin D supplementation, with consideration beyond bone health, is warranted and should focus on randomised controlled trials.

Abstract Maternal BMI has been shown to be inversely correlated with vitamin D status (25-hydroxyvitamin D (25(OH)D) concentrations) during pregnancy. Pregnant women with obesity and with vitamin D deficiency are at risk of many adverse health outcomes in pregnancy. The aim of this study was to examine differences in maternal vitamin D status across normal weight, overweight and obese pregnant women in early pregnancy. Data collected at baseline from a double-blind randomised vitamin D intervention study (MO-VITD) were used. Pregnant women without pregnancy complications, aged > 18 years and having a singleton pregnancy were recruited between January 2016 and August 2017 at antenatal clinics in the Western Health and Social Care Trust, Northern Ireland. Non-fasting blood samples were collected at 12 weeks gestation and analysed for total serum 25(OH)D, using liquid chromatography tandem mass spectrometry. Data from 239 pregnant women (80 normal weight, 79 overweight, 80 obese) were included in the current analysis. The mean ± SD 25(OH)D concentration of all pregnant women at 12 weeks gestation was 52.0 ± 21.6 nmol/L. Women classed as obese or overweight had significantly lower 25(OH)D concentrations compared to women of normal weight (48.8 ± 20.3 vs 49.8 ± 20.4 vs. 57.5 ± 23.1 nmol/L, P = 0.019; obese, overweight, normal weight respectively). A total of 45% of all pregnant women were found to be either vitamin D deficient (25(OH)D < 25nmol/L; 13%) or insufficient (25–50 nmol/L; 32%) in early pregnancy. BMI was significantly negatively correlated with 25(OH)D concentrations (r = -0.168; P = 0.009). Regression analyses showed that BMI (β = -0.165; P = 0.006), season (β = 0.220; P = < 0.0001), supplement use (β = -0.268; P < 0.0001) and a sun holiday within the previous 6 months (β = -0.180; P = 0.010) were significant predictors of 25(OH)D concentrations. In early pregnancy, 62% of pregnant women reported using a supplement containing vitamin D and 38% reported no supplement use. Supplement users had a significantly higher vitamin D status than non-supplement users in all BMI categories but overall, 37% of supplement users were still classified as vitamin D insufficient. Vitamin D status was significantly lower in winter months compared to summer months. In early pregnancy, especially during winter months, pregnant women with obesity, particularly non-supplement users, are at higher risk of low vitamin D status. Based on the lower vitamin D status observed in early pregnancy in obese women, the effect of BMI on vitamin D supplementation throughout pregnancy needs to be examined.

AbstractPregnant women who are overweight/obese are particularly vulnerable to vitamin D insufficiency owing to higher physiological requirements and lower status (25(OH)D concentrations) associated with obesity. Achieving adequate maternal vitamin D status with current recommendations (10μg/d) remains controversial.This study examined supplementation effects (10μg-vs-20μg vitamin D3/d) throughout pregnancy (12 weeks gestation until delivery) on vitamin D status of normal weight, overweight and obese pregnant women and on cord blood, using a double-blind randomised vitamin D intervention study (MO-VITD). 240 pregnant women were recruited throughout the year at antenatal clinics in Northern Ireland (equal numbers of normal weight (18.5–24.9 kg/m2), overweight (25–29.9 kg/m2), and obese (> 30kg/m2)). Non-fasting maternal blood samples were collected at 12, 28 and 34–36 weeks gestation and from the umbilical cord after delivery and analysed for total serum 25(OH)D using LCMS.A high prevalence of vitamin D insufficiency (25–50nmol/L) was found in the 1st trimester in both treatment groups (41.5% and 48.8%; 10μg vs. 20μg respectively). Maternal 25(OH)D concentrations increased from the 1st to 3rd trimester in both the 10μg/d and 20μg/d groups, with a higher increase in the 20μg group (17.1 ± 24.7 and 28.8 ± 33.3nmol/L, P = 0.002). There was no difference in cord blood 25(OH)D concentrations between treatment groups.Women who started pregnancy with insufficient 25(OH)D concentrations remained insufficient throughout pregnancy in the 10μg/d group (49.9 ± 28.2nmol/L at trimester 3). In the 20μg/d group, women starting pregnancy as insufficient achieved levels of sufficiency in the 2nd (58.9 ± 30.6nmol/L) and 3rd (64.0 ± 35.9nmol/L) trimesters. Women who started pregnancy with sufficient vitamin D status (25(OH)D > 50nmol/L), maintained levels of sufficiency throughout pregnancy irrespective of treatment group (83.1 ± 24.4 and 96.7 ± 30.7 at trimester 3 in 10μg/d and 20 μg/d groups respectively); findings were similar across all BMI categories.Obese women who started pregnancy with an insufficient status were found to have deficient cord blood (25(OH)D < 25 nmol/L) in both the 10μg/d and 20μg/d groups (19.4 ± 20.2 vs. 19.5 ± 9.4nmol/L respectively), whilst obese women who started pregnancy with sufficient status (> 50nmol/L) had cord blood concentrations considered insufficient (40.2 ± 18.4 vs. 44.2 ± 15.6nmol/L; 10μg vs. 20μg groups respectively).Based on our findings of the high prevalence of vitamin D insufficiency in early pregnancy, maternal vitamin D supplementation of 20μg/d is advisable to maintain maternal vitamin D status in pregnant women in Northern Ireland.

Context: Emerging evidence suggests that deficiencies of folate-related B vitamins can arise with metformin treatment and are independently linked with cognitive dysfunction, a comorbidity of diabetes. Objective: To determine the impact of hyperglycemia and metformin use on relevant B vitamin biomarkers and cognitive outcomes in older adults. Setting and Participants: Community-dwelling older adults (74.1 +/- 8.3 years, n = 4160) without dementia, recruited to the Trinity, Ulster and Department of Agriculture cohort study in 2008 to 2012, were classified as normoglycemic (n = 1856) or hyperglycemic, based on HbA1c (39 mmol/mol), either with (n = 318) or without (n = 1986) metformin treatment. Main Outcome Measures: Biomarkers of folate, vitamin B12, vitamin B6, and riboflavin were measured. Cognitive assessments included the Repeatable Battery for Assessment of Neuropsychological Status (RBANS) and the Frontal Assessment Battery (FAB). Results: Metformin use was associated with higher risk of deficiency of vitamin B12 (combined B12 index <= -1; OR 1.45; 95% CI, 1.03 to 2.02) and vitamin B6 (plasma pyridoxal 5phosphate <30.0 nmol/L; OR 1.48; 95% CI, 1.02 to 2.15). Fortified foods when eaten regularly had a positive impact on all relevant B vitamin biomarkers, even with hyperglycemia. After adjustment for relevant covariates, metformin use was associated with an increased risk of cognitive dysfunction as assessed with the RBANS (OR 1.36; 95% CI, 1.03 to 1.80) and FAB (OR 1.34; 95% CI, 1.03 to 1.74). Conclusions: Use of metformin by older adults is associated with poorer cognitive performance; B vitamin deficiency may be implicated. Fortified foods can optimize B vitamin status and may be beneficial for maintaining better cognitive health in older people with or at risk for diabetes.

Abstract Following an application from Lonza Ltd., submitted for authorisation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Germany, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to L‐carnitine and normal lipid metabolism. The food that is proposed as the subject of the health claim is L‐carnitine. The Panel considers that L‐carnitine is sufficiently characterised. The claimed effect proposed by the applicant is ‘normal lipid metabolism’. The target population proposed by the applicant is the general population. The Panel considers that contribution to normal lipid metabolism is a beneficial physiological effect. The applicant proposes that the claim submitted with this application is based on the essentiality of a nutrient. The Panel considers that the evidence provided does not establish that dietary L‐carnitine is required to maintain normal lipid metabolism in the target population, for which the claim is intended. The Panel concludes that a cause and effect relationship has not been established between the consumption of L‐carnitine and contribution to normal lipid metabolism in the target population.

Abstract Following an application from Newtricious R&D B.V., submitted for authorisation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of the Netherlands, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to NWT‐02 and a reduction of the loss of vision. The food proposed by the applicant as the subject of the health claim is NWT‐02. NWT‐02 is standardised by its content in lutein (≥ 1.10 mg), zeaxanthin (≥ 0.20 mg) and docosahexaenoic acid (DHA) (≥ 170 mg). The Panel considers that the food/constituent that is the subject of the health claim, NWT‐02, a fixed combination of lutein, zeaxanthin and docosahexaenoic acid in egg yolk, is sufficiently characterised. The claimed effect proposed by the applicant is ‘reduces loss of vision’. The target population proposed by the applicant is ‘healthy adults over 50 years of age’. The Panel considers that a reduction of the loss of vision is a beneficial physiological effect. The applicant provided two human intervention studies for the scientific substantiation of the claim. The Panel considers that the only study from which conclusions can be drawn for the scientific substantiation of the claim did not show an effect of NWT‐02 on vision. The Panel concludes that a cause and effect relationship has not been established between the consumption of NWT‐02, a fixed combination of lutein, zeaxanthin and docosahexaenoic acid in egg yolk, and a reduction of the loss of vision.

Abstract Following an application from Specialised Nutrition Europe (SNE), submitted for authorisation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of France, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to carbohydrate solutions and contribute to the improvement of physical performance during a high‐intensity and long‐lasting physical exercise. The scope of the application was proposed to fall under a health claim based on newly developed scientific evidence. The food proposed by the applicant as the subject of the health claim is carbohydrate solutions containing glucose, mixtures of glucose and fructose, sucrose and/or maltodextrins. The Panel considers that carbohydrate solutions are sufficiently characterised in relation to the claimed effect. The claimed effect proposed by the applicant is ‘contribute to the improvement of physical performance during a high‐intensity and long‐lasting physical exercise’, which is considered by the Panel as a beneficial physiological effect. The Panel concludes that a cause and effect relationship has been established between the consumption of carbohydrate solutions and the improvement of physical performance during high‐intensity and long‐lasting physical exercise. The target population is healthy trained adults performing high‐intensity (at least at 65% of the VO2max) and long‐lasting (at least 60 min) physical exercise.

Abstract Following an application from Unilever NV, submitted for authorisation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Ireland, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to black tea and improvement of attention. The scope of the application was proposed to fall under a health claim based on newly developed scientific evidence. The food proposed by the applicant as the subject of the health claim is black tea. The Panel considers that black tea characterised by its content of tea solids, caffeine and l‐theanine, which is the subject of the health claim, is sufficiently characterised in relation to the claimed effect. The claimed effect proposed by the applicant is ‘improves attention’. The Panel considers that improvement of attention is a beneficial physiological effect. Three human intervention studies provided by the applicant show an effect of black tea on attention under the conditions of used proposed by the applicant. The applicant proposed that the claimed effect depends on the concerted action of two substances, caffeine and l‐theanine, both of which are present in black tea. The Panel considers that the effect of black tea on attention observed in the three human intervention studies provided by the applicant can be explained by its caffeine content. The Panel concludes that a cause and effect relationship has been established between the consumption of black tea and improvement of attention. The Panel considers that the effect of black tea on attention can be explained by its caffeine content. The following wording reflects the scientific evidence: ‘Owing to its caffeine content, black tea improves attention’. In order to obtain the claimed effect, 2–3 servings of black tea providing at least 75 mg of caffeine in total should be consumed within 90 min.

Following an application from Federacion Nacional de Industrias Latcteas ( FeNIL), submitted pursuant to Article 13.5 of Regulation ( EC) No 1924/ 2006 via the Competent Authority of Spain, the Panel on Dietetic Products, Nutrition and Allergies ( NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to fat- free yogurts and fermented milks complying with the specifications "fat free", "low in sugars", "high protein", "source of calcium" and "source of vitamin D" for nutrition claims and reduction of body and visceral fat while maintaining lean body mass in the context of an energy-restricted diet. The food that is the subject of the claim is fat- free yogurts and fermented milks complying with the specifications "fat free", "low in sugars", "high protein", "source of calcium" and "source of vitamin D" for nutrition claims. The Panel considers that fat- free yogurts and fermented milks complying with the specifications "fat free", "low in sugars", "high protein", "source of calcium" and "source of vitamin D" for nutrition claims are sufficiently characterised. The Panel considers that reduction of body and visceral fat mass while maintaining lean body mass in the context of an energy-restricted diet is a beneficial physiological effect. No human intervention studies from which conclusions could be drawn for the scientific substantiation of the claim were provided. The Panel concludes that a cause and effect relationship has not been established between the consumption of fat- free yogurts and fermented milks complying with the specifications "fat free", "low in sugars", "high protein", "source of calcium" and "source of vitamin D" for nutrition claims and reduction of body and visceral fat mass while maintaining lean body mass in the context of an energy-restricted diet. (C) European Food Safety Authority, 2015.

Following an application from Tchibo GmbH, submitted for authorisation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Germany, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to coffee C21 and reduction of DNA damage by decreasing spontaneous DNA strand breaks. The scope of the application was proposed to fall under a health claim based on newly developed scientific evidence. Coffee C21, a coffee standardised by its content of caffeoylquinic acids, trigonelline and N-methylpyridinium (NMP), which is the subject of the health claim, is sufficiently characterised. Reduction of DNA damage by decreasing spontaneous DNA strand breaks is a beneficial physiological effect. In weighing the evidence, the Panel took into account that one human intervention study showed that daily consumption of coffee C21 (750 ml/day) for four weeks decreased spontaneous DNA strand breaks in habitual coffee drinkers after coffee withdrawal over the previous four weeks, but that no other human studies in which these results have been replicated were provided, and that no evidence was provided for a mechanism by which coffee (including coffee C21) could exert the claimed effect. The Panel concludes that a cause and effect relationship has not been established between the consumption of coffee C21, a coffee standardised by its content of caffeoylquinic acids, trigonelline and NMP, and a reduction of DNA damage by decreasing spontaneous DNA strand breaks. (C) European Food Safety Authority, 2015.